Advertisement

Clinical and Translational Oncology

, Volume 8, Issue 6, pp 399–408 | Cite as

Therapeutic opportunities to control tumor cell cycles

  • Marcos MalumbresEmail author
Educational Series Green Series

Abstract

Tumor cell proliferation is frequently associated to genetic or epigenetic alterations in key cell cycle regulators. Most human tumors deregulate this pathway to sustain proliferation with independence of external mitogenic factors. In addition, the alteration of cell cycle proteins may confer genomic instability that results in additional mutations in these tumor cells. The frequent alteration of the cell cycle in tumor cells has launched the identification for critical cell cycle regulators as anticancer targets. The inhibition of some cell cycle kinases such as cyclin-dependent kinases (CDKs) or the Aurora and Polo mitotic kinases is currently under study in several preclinical and clinical trials. Similarly, the clinical success of microtubule poisons such as taxol has promoted new applied research in mitosis regulation. Recent investigations have suggested new targets of interest including additional kinases, phosphatases and other mitotic regulators such as microtubule motor proteins (kinesins). Current research in this area will undoubtedly result in new and improved targeted therapies for cancer treatment.

Key words

cyclin-dependent kinases Aurora Polo phosphatases kinesins cell cycle genomic instability cancer therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Malumbres M, Barbacid M. RAS oncogenes: the first 50 years. Nat Rev Cancer. 2003;3:459–65.PubMedCrossRefGoogle Scholar
  2. 2.
    Nurse, P. A long twentieth century of the cell cycle and beyond. Cell. 2000;100:71–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Massague, J.. G1 cell-cycle control and cancer. Nature 2004;432:298–306.PubMedCrossRefGoogle Scholar
  4. 4.
    Malumbres M, Barbacid M. To cycle or no to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222–31.PubMedCrossRefGoogle Scholar
  5. 5.
    Malumbres M, Carnero A. Cell cycle deregulation: a common motif in cancer. Progress Cell Cycle Res. 2003;5:5–18.Google Scholar
  6. 6.
    Ortega S, Malumbres M, Barbacid M. Cdk4 and their INK4 inhibitors in tumor biology. Biochem Biophys Acta. 2002;87513:1–15.Google Scholar
  7. 7.
    Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30:630–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Ciemerych MA, Sicinski P. Cell cycle in mouse development. Oncogene. 2005;24: 2877–98.PubMedCrossRefGoogle Scholar
  9. 9.
    Senderowicz AM. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol. 2004;16: 670–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Hirai H, Kawanishi N, Iwasawa Y. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Curr Top Med Chem. 2005; 5:167–79.PubMedCrossRefGoogle Scholar
  11. 11.
    Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Ventura JJ, Nebreda AR. Protein kinases and phosphatases as therapeutic targets in cancer. Clin Transl Oncol. 2006;8:153–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Blagosklonny MV. Flavopiridol, an inhibitor of transcription. Implications, problems and solutions. Cell Cycle. 2004;3: 1557–42.Google Scholar
  14. 14.
    Malumbres M, Barbacid M. Is Cyclin D1/Cdk4 kinase a bona-fide cancer target? Cancer Cell. 2006;9:2–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Bartek J, Lukas C, Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol. 2004;5:792–804.PubMedCrossRefGoogle Scholar
  16. 16.
    Gottifredi V, Prives C. The S phase checkpoint: when the crowd meets at the fork. Semin Cell Dev Biol. 2005;16:355–68.PubMedCrossRefGoogle Scholar
  17. 17.
    Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther. 2004; 3:513–9.PubMedGoogle Scholar
  18. 18.
    Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol. 2001;1:370–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Hadfield JA, Ducki S, Hirst N, McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res. 2003;5:309–25.PubMedGoogle Scholar
  20. 20.
    Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:255–65.CrossRefGoogle Scholar
  21. 21.
    Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005; 5:773–85.PubMedCrossRefGoogle Scholar
  22. 22.
    Tao W. The mitotic checkpoint in cancer therapy. Cell Cycle. 2005;4:e103-e7.Google Scholar
  23. 23.
    Schmidt M, Medema RH. Exploiting the compromised spindle assembly checkpoint function of tumor cells: dawn on the horizon? Cell Cycle. 2006;5:159–163.PubMedGoogle Scholar
  24. 24.
    Doxsey S, McCollum D, Theurkauf W. Centrosomes in cellular regulation. Annu Rev Cell Dev Biol. 2005;21:411–34.PubMedCrossRefGoogle Scholar
  25. 25.
    Tsou MF, Stearns T. Controlling centrosome number: licenses and blocks. Curr Opin Cell Biol. 2006;18:74–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2:21–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Petretti C, Savoian M, Montembault E, Glover DM, Prigent C, Giet R. The PIT-SLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO Rep. 2006;7:418–24.PubMedGoogle Scholar
  28. 28.
    Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4:842–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 2004;4:927–36.PubMedCrossRefGoogle Scholar
  30. 30.
    Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle asembly checkpoint, inducing resistance to taxol. Cancer Cell. 2003;3:51–62.PubMedCrossRefGoogle Scholar
  31. 31.
    Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growthin vivo. Nat Med. 2004;10:262–267.PubMedCrossRefGoogle Scholar
  32. 32.
    Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004;5:429–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006;6:321–30.PubMedCrossRefGoogle Scholar
  34. 34.
    Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe plk1 depletion. Mol Cell Biol. 2006;26:2093–108.PubMedCrossRefGoogle Scholar
  35. 35.
    Jallepalli PV, Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer. 2001;1:109–17.PubMedCrossRefGoogle Scholar
  36. 36.
    Baker D, Chen J, Deursen JMA. The mitotic checkpoint in cancer and aging: what have mice taught us? Curr Opin Cell Biol. 2005;17:583–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Quarmby LM, Mahjoub MR. Caught Neking: cilia and centrioles. J Cell Sci. 2005; 118:5161–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett. 2005; [doi:10.1016/j.canlet. 2005. 06.017].Google Scholar
  39. 39.
    Fisk HA, Mattison CP, Winey M. A field guide to the Mps1 family of protein kinases. Cell Cycle 2004;3:439–42.PubMedGoogle Scholar
  40. 40.
    Dorer RK, Zhong S, Tallarico JA, Wong WH, Mitchison TJ, Murray AW. A small-molecule inhibitor of Mps1 blocks the spindle-checkpoint response to a lack of tension on mitotic chromosomes. Curr Biol. 2005;15:1070–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Schmidt M, Budirahardja Y, Klompmaker R, Medema RH. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep. 2005;6:866–72.PubMedCrossRefGoogle Scholar
  42. 42.
    Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 2003;4:671–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Eckstein JW. Cdc25 as a potential target of anticancer agents. Invest New Drugs. 2000;18:149–56.PubMedCrossRefGoogle Scholar
  44. 44.
    Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol. 2004;11: 1043–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Stegmeier F, Amon A. Closing mitosis: the functions of the Cdc14 phosphatase and its regulation. Annu Rev Genet. 2004;38: 203–32.PubMedCrossRefGoogle Scholar
  46. 45.
    Mailand N, Lukas C, Kaiser BK, Jackson PK, Bartek J, Lukas J. Deregulated human Cdc14A phosphatase disrupts centrosome separation and chromosome segregation. Nat Cell Biol. 2002;4:317–322.PubMedCrossRefGoogle Scholar
  47. 46.
    Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999;286:971–4.PubMedCrossRefGoogle Scholar
  48. 47.
    Bergnes G, Brejc K, Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem. 2005;5:127–45.PubMedCrossRefGoogle Scholar
  49. 48.
    Duhl DM, Renhowe PA. Inhibitors of kinesin motor proteins-research and clinical progress. Curr Opin Drug Discov Devel. 2005;8:431–6.PubMedGoogle Scholar
  50. 49.
    Carleton M, Mao M, Biery M, et al. RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induced cytokinesis failure. Mol Cell Biol. 2006;26:3853–63.PubMedCrossRefGoogle Scholar
  51. 50.
    Malumbres M. Revisiting the “Cdk-centric” view of the mammalian cell cycle. Cell Cycle. 2005;4:206–10.PubMedGoogle Scholar
  52. 51.
    Sotillo R, Renner O, Dubus P, et al. Cooperation between Cdk4 and p27Kip1 in Tumor Development: a Preclinical Model to Evaluate Cell Cycle Inhibitors with Therapeutic Activity. Cancer Res. 2005;65:3846–52.PubMedCrossRefGoogle Scholar
  53. 52.
    Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005;8:7–12.PubMedCrossRefGoogle Scholar
  54. 53.
    Eggert US, Kiger AA, Richter C, et al. Parallel chemical genetic and genomewide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol. 2004;2: 2135–43.CrossRefGoogle Scholar
  55. 54.
    Toogood PL. Progress toward the development of agents to modulate the cell cycle. Curr Opin Chem Biol. 2002;6:472–8.PubMedCrossRefGoogle Scholar
  56. 55.
    Prevost GP, Brezak MC, Goubin F, et al. Inhibitors of the CDC25 phosphatases. Prog Cell Cycle Res. 2003;5:225–34.PubMedGoogle Scholar
  57. 56.
    Brezak MC, Quaranta M, Mondesert O, et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res. 2004; 64:3320–5.PubMedCrossRefGoogle Scholar
  58. 57.
    Skoufias DA, Debonis S, Saoudi Y, et al. S-trityl-l-cysteine is a reversible, tight-binding inhibitor of the human kinesin eg5 that specifically blocks mitotic progression. J Biol Chem. 2006 [J. Biol. Chem, 10.1074/jbc.M511735200].Google Scholar

Copyright information

© FESEO 2006

Authors and Affiliations

  1. 1.Cell Division and Cancer GroupCentro Nacional de Investigaciones Oncológicas (CNIO)MadridSpain

Personalised recommendations